All In Biotech

Drug Trial Radar · NCT03108495

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

210

Actual

Start

Jun 22, 2017

Primary completion

Aug 22, 2025

Study completion Aug 22, 2025

Sponsor

Lead sponsor
Iovance Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.

Conditions

  • Cervical Carcinoma

Interventions

  • LN-145Biological

    A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.

  • LN-145 + pembrolizumabBiological

    A tumor sample is resected from each participant and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort 1 and 2: Objective Response RateTime frame: Up to 60 months
  2. Cohort 3: Number of Participants With Adverse EventsTime frame: Up to 60 months
  3. Cohort 4: Number of Participants With Adverse EventsTime frame: Up to 60 months
  4. Cohort 4: Efficacy/Objective Response RateTime frame: Up to 60 months
  5. Cohort 5: Number of Participants With Adverse EventsTime frame: Up to 60 months
  6. Cohort 5: Efficacy/Objective Response RateTime frame: Up to 60 months

Locations

43 sites in 8 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center Center For Women's Health

    Phoenix, Arizona

  • University of Southern California

    Los Angeles, California

  • University of California San Diego

    San Diego, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • University of Florida Health Cancer Center

    Orlando, Florida

  • University of South Florida H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Augusta University

    Augusta, Georgia

  • University of Chicago

    Chicago, Illinois

  • James Graham Brown Cancer Center

    Louisville, Kentucky

  • LSU Health Sciences Center

    New Orleans, Louisiana

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Rutgers University

    Newark, New Jersey

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Allegheny Health

    Pittsburgh, Pennsylvania

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • Avera Medical Group Oncology

    Sioux Falls, South Dakota

  • MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Centre Léon Bérard

    Lyon, France

  • Gustave Roussy Cancer Campus

    Villejuif, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, Auvergne-Rhône-Alpes, France

  • Universitätsklinikum Erlangen

    Erlangen, Bavaria, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, Germany

  • Istituto Europeo di Oncologia

    Miano, Milano, Italy

  • Academisch Medisch Centrum

    Amsterdam, AZ, Netherlands

  • Hospital Universitari Vall d'Hebrón

    Barcelona, Spain

  • Institut Català d'Oncologia

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Universitario Madrid Sanchinarro

    Madrid, Spain

  • Clínica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Inselspital

    Bern, Switzerland

  • Centre Hospitalier Universitaire Vaudois Lausanne - Centre Pluridisciplinaire d'Oncologie

    Lausanne, Switzerland

  • Guy's & St.Thomas NHS Foundation Trust

    London, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.